Abstract
The effectiveness of sulphanilamide (para amino benzene sulphonamide) in the treatment of certain bacterial infections 1 suggested its trial in the treatment of a virus infection, experimental poliomyelitis. Though no reports of the use of sulphanilamide in any virus diseases have appeared, Long 2 has observed no improvement of concurrent common colds in patients receiving the drug for various streptococcal infections. Marshall and his associates 3 have shown that sulphanilamide diffuses readily through the tissues of the body, and into the cerebrospinal fluid, where it reaches a level slightly lower than that of the blood stream. Two bacterial infections of the meninges, Beta hemolytic streptococcal meningitis 4 and menin-gococcal meningitis 5 have responded well to sulphanilamide therapy.
Two series of Macacus rhesus monkeys were used in these experiments. The first 4 monkeys were inoculated by the intranasal route with 0.5 cc. of 20% fresh virus cord suspension in each nostril on 2 successive days; two of these monkeys received subcutaneous injections of 50 cc. of a 1% saline solution of sulphanilamide‡ (an amount equal proportionately to twice the maximal therapeutic human dose) twice daily, begun 3-4 hours prior to the first inoculation of the virus suspension; two were used as controls. In the second group, 6 monkeys received one cc. each of 15% virus cord suspension in each nostril on 2 successive days; 4 were given sulphanilamide as above, while 2 control animals received 50 cc. of normal saline subcutaneously twice daily. Tables I and II show the course of these monkeys.
It is seen that in the 2 series of experiments 2 monkeys survived, one treated animal, after transient paralysis, and a control animal showing marked, but very gradually diminishing, paralysis. Such survivals are not uncommon in untreated animals following inoculation by the intranasal route.
Get full access to this article
View all access options for this article.